• Ahead MiMiTOPs display a broad, cross-disease mechanism of action
• Antigen-presenting cells from patients with T1D, RA, MG, MS and iTTP acquire a tolerogenic phenotype following interaction with MiMiTOPs. Dendritic cells and macrophages become tolerogenic, reducing their ability to drive autoreactive T cell proliferation, while B lymphocytes directly internalize MiMiTOPs and secrete TGF-β and IL-10, adopting an immunoregulatory phenotype
• Through coordinated effects on innate and adaptive immunity, MiMiTOPs provide an antigen-specific strategy to support long-term immune tolerance

NEW DATA